Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: An automated immunological assay apparatus is disclosed. The apparatus includes a frame carrying device for supporting samples to be analyzed, a device for supporting reagents, and a device for displacing sets of reaction wells along a rectangular path. A cog belt extends along the long sides of the path and a mechanism for transverse displacement extends along the short sides of the path. A device is also provided at one end of the path for automatically feeding sets of reaction wells.

Abstract: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds.

Abstract: Novel phenylcyclohexanes of the formula I in which n is 0 to 7, Q1 and Q2 are H, or one of these radicals is alternatively CH3, r is 0, 1, 2, 3, 4 or 5, A is trans-1,4-cyclohexylene, 1,4-phenylene, 3-fluoro-1,4-phenylene or a single bond, X is F, Cl, —CF3, —CN, —OCF3 or —OCHF2, and Y and Z are each, independently of one another, H or F, with the proviso that, in the case where A is a single bond, Q1=Q2=H and simultaneously X=CN, Y and/or Z are F.

Abstract: Provided herein are nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. In one aspect of the invention, the nucleic acids encode provides In a preferred embodiment, the invention nucleic acids encode MNDAR1, NMDAR2A, NMDAR2B, NMDAR2C and NMDAR2D subunits of human NMDA receptors. The disclosed nucleic acids are also useful as probes, thus enabling those skilled in the art, to identify and isolate related human receptor subunits. Functional glutamate receptors can be assembled, in accordance with the present invention, from a plurality of one type of NMDA receptor subunit protein (homomeric) or from a mixture of two or more types of subunit proteins (heteromeric). Also provided are methods for using the disclosed receptor subunits to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.

Abstract: The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.

Abstract: An anisotropic polymer film comprising a polymeriZed chiral liquid crystal material with helically twisted structure and having areas with different helical twist sense is useful for decorative or security applications.

Abstract: The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Abstract: The invention generally relates to the use of poly-3,3?-dialkyl-2,2?:5?,2?-terthiophenes as charge transport materials or semiconductors in electrooptical, electronic or electroluminescent devices, and to charge transport and semiconducting components and devices comprising poly-3,3?-dialkyl-2,2?:5?,2?-terthiophenes.

Abstract: A liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, which contains: one or more compounds of the general formula I ?in which R, ?Y, Z and n are as defined in claim 1, one or more compounds of the following formulae IIa, IIb, IIc and IId and one or more compounds of the formula in which Ro, Xo, Y2 and r are as defined in claim 1.

Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.

Abstract: A liquid-crystalline medium having a mixture of polar compounds of positive dielectric anisotropy is described.

Abstract: The invention relates to agents and processes for detecting bacteria of the genus Listeria, in particular L. monocytogenes. The agents according to the invention include primers whose sequence is selected from the iap gene of L. monocytogenes. In addition, the agents according to the invention include peptides whose sequence is selected from the p60 protein and which are suitable for producing specific antibodies for the immunological detection of L. monocytogenes.

Abstract: A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABAA receptors of formula I which are partial or full inverse agonists of an ?5 receptor subunit while being relatively free of activity at ?1 and/or ?2 and/or ?3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.

Abstract: This invention provides isolated polynucleotides that encode the MurF (UDP-N-acetylmuramyl-L-alanine-D-glutamate-m-DaD:D-alanine-D-alanine ligase) protein of Pseudomonas aeruginosa. Purified and isolated MurF recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurF proteins are described. Assays for the identification of modulators of the expression of murF and inhibitors of the activity of MurF, are also provided.

Abstract: The present invention provides trichloroethyl-sulfonylurea-containing compounds that inhibit glycing transporters, pharmaceutical compositions comprising such compounds, methods for using such compounds for inhibiting glycine transporters and methods for using such compounds for the treatment of disease states in which glycine is involved.

Abstract: A class of substituted imadazolo[2,1-a]phthalazine derivatives as ligands for GABAA receptors of formula I: which are partial or full inverse agonists of an ?5 receptor subunit while being relatively free of activity at ?1 and/or ?2 and/or ?3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.

Abstract: The invention relates to compounds of the formula I in which R1, R2, R3, R4 and X have the meaning indicated in the text. The compounds act as inhibitors of factors Xa and VIIa and can therefore be employed for the control and prevention of thromboembolic conditions such as thrombosis, myocardial infarct, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

Abstract: The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.